Finally, combined treatment with anti–PD-L1 antibody and G9668 in the EMT6 TNBC model, which was only partially responsive to anti–PD-L1, led to clear tumor regression, suggesting a non-redundant complementarity of these two modalities. This evidence concerns the gene CD274 and neoplasm.